Discover
IMVT
Immunovant, Inc.
39.53
1 x 37.27
1 x 40.49
bid
ask
-
0.39
0.98%
1 @ 04:00 PM
39.11 -0.42 (1.06%)
| Ytd | 55.51% | |
| 1y | 120.35% |
39.33
day range
40.25
14.32
52 week range
41.23
| Open | 39.76 | Prev Close | 39.92 | Low | 39.33 | High | 40.25 | Mkt Cap | 8.12B |
| Vol | 1.25M | Avg Vol | 1.82M | EPS | -2.67 | P/E | -14.81 | Forward P/E | -16.30 |
| Beta | 0.76 | Short Ratio | 10.32 | Inst. Own | 54.62% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 34.80 | 200-d Avg | 27.16 | 1yr Est | 47.19 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-10 | 2026-06 | -0.66 | N/A | N/A | N/A |
| 2026-05-20 | 2026-03 | -0.59 | -0.73 | -0.14 | -23.31% |
| 2026-02-06 | 2025-12 | -0.72 | -0.61 | 0.11 | 15.28% |
| 2025-11-10 | 2025-09 | -0.72 | -0.73 | -0.01 | -1.39% |
| 2025-08-11 | 2025-06 | -0.69 | -0.6 | 0.09 | 13.04% |
| 2025-05-29 | 2025-03 | -0.71 | -0.64 | 0.07 | 10.27% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-30 | Citigroup | Upgrade | Buy | Buy |
| 2026-05-26 | Guggenheim | Upgrade | Buy | Buy |
| 2026-05-22 | Truist Securities | Upgrade | Hold | Hold |
| 2026-05-21 | B of A Securities | Upgrade | Buy | Buy |
| 2026-05-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-04-15 | Goldman Sachs | Upgrade | Neutral | Neutral |
Profile
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-04-15 | BARNETT EVA RENEE | Chief Financial Officer | 396.77K | Sale |
| 2024-08-20 | BUTCHKO JULIA G | Officer | 440.96K | Sale |
| 2026-06-25 | GIRÃO TIAGO M | Chief Financial Officer | 247.60K | Conversion of Exercise of derivative security |
| 2026-07-07 | GLORIA MELANIE | Chief Operating Officer | 222.36K | Sale |
| 2024-11-19 | LEVINE MARK S | Officer | 319.23K | Sale |
| 2025-02-18 | MACIAS WILLIAM L | Officer | 357.35K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR Inc | 16.95M | 0.00 | 8.25% |
| 2026-03-30 | Deep Track Capital, LP | 11.53M | 0.00 | 5.61% |
| 2025-12-30 | Vanguard Group Inc | 7.78M | 0.00 | 3.79% |
| 2026-03-30 | BlackRock Inc | 6.57M | 0.00 | 3.20% |
| 2026-03-30 | Baker Bros Advisors LP | 5.46M | 0.00 | 2.66% |
| 2026-03-30 | State Street Corp | 4.54M | 0.00 | 2.21% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Growth Compy Commingled Pl S | 6.94M | 0.00 | 3.38% |
| 2026-05-30 | Fidelity Growth Company Fund | 5.10M | 0.00 | 2.48% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 2.60M | 0.00 | 1.27% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 2.57M | 0.00 | 1.25% |
| 2026-06-29 | iShares Russell 2000 ETF | 2.20M | 0.00 | 1.07% |
| 2026-06-29 | Vanguard Small Cap Index | 1.88M | 0.00 | 0.92% |